WO1997038701A1 - Composition et procede pour le traitement du syndrome premenstruel - Google Patents
Composition et procede pour le traitement du syndrome premenstruel Download PDFInfo
- Publication number
- WO1997038701A1 WO1997038701A1 PCT/CA1996/000229 CA9600229W WO9738701A1 WO 1997038701 A1 WO1997038701 A1 WO 1997038701A1 CA 9600229 W CA9600229 W CA 9600229W WO 9738701 A1 WO9738701 A1 WO 9738701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- magnesium
- present
- diuretic
- analgesic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 206010036618 Premenstrual syndrome Diseases 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 22
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000011575 calcium Substances 0.000 claims abstract description 22
- 239000011777 magnesium Substances 0.000 claims abstract description 22
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 21
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 21
- 239000002934 diuretic Substances 0.000 claims abstract description 18
- 230000001882 diuretic effect Effects 0.000 claims abstract description 18
- 230000000202 analgesic effect Effects 0.000 claims abstract description 17
- 208000024891 symptom Diseases 0.000 claims description 26
- 229940091250 magnesium supplement Drugs 0.000 claims description 20
- 229960005069 calcium Drugs 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- OKRXSXDSNLJCRS-NLOQLBMISA-L calcium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate;hydrate Chemical compound O.[Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O OKRXSXDSNLJCRS-NLOQLBMISA-L 0.000 claims description 6
- 229960005489 paracetamol Drugs 0.000 claims description 6
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- ATOTUUBRFJHZQG-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 ATOTUUBRFJHZQG-UHFFFAOYSA-N 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 229960003563 calcium carbonate Drugs 0.000 claims description 4
- 239000001755 magnesium gluconate Substances 0.000 claims description 4
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 4
- 229960003035 magnesium gluconate Drugs 0.000 claims description 4
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 4
- 229960003357 pamabrom Drugs 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 229960002713 calcium chloride Drugs 0.000 claims description 3
- 229960002283 calcium glubionate Drugs 0.000 claims description 3
- 229960002562 calcium glucoheptonate Drugs 0.000 claims description 3
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- JQAACYUZYRBHGG-QHTZZOMLSA-L magnesium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Mg+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 JQAACYUZYRBHGG-QHTZZOMLSA-L 0.000 claims description 3
- RPFBVONPMGMOOW-UHFFFAOYSA-N magnesium;2-oxopyrrolidine-1-carboxylic acid Chemical compound [Mg].OC(=O)N1CCCC1=O RPFBVONPMGMOOW-UHFFFAOYSA-N 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 229940078512 calcium gluceptate Drugs 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 206010016807 Fluid retention Diseases 0.000 description 6
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010006313 Breast tenderness Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 208000013404 behavioral symptom Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010065347 Premenstrual pain Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- -1 calcium cations Chemical class 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940096405 magnesium cation Drugs 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 238000009140 magnesium supplementation Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Definitions
- the present invention relates to therapeutic compositions and methods and in particular compositions and methods for treatment of an individual exhibiting symptoms of premenstrual syndrome.
- PMS premenstrual syndrome
- PMS The specific etiology of PMS remains unknown, although many theories have been proposed. These include: hormonal imbalances, hormonal deficiencies, vitamin deficiencies, disturbances of the autonomic nervous system, salt and water imbalances, altered endogenous opiates and psychosomatic dysfunction.
- M.Ferin, R.Jewelewicz and M.Warren The Menstrual Cvcle; Physiology. Reproductive Disorders, and Infertility, pp. 198-204 (1993).
- PMS is multifactorial and probably also involves changes in neurohormones and neurotransmitters, which are not easily documented in humans. Numerous attempts have been made to develop an effective treatment for the symptoms of PMS. Dietary modification including reduction of salt, alcohol, and beverages containing caffeine have been suggested. Pharmacologic intervention is commonly used, especially progesterone therapy and hypothalamic-pituitary-ovarian axis suppressors.
- Nonprescription pharmacologic compositions have also been made available. Most provide aspirin or acetaminophen as an analgesic for diminishing menstrual pain. Calcium has also been found to be an effective treatment, especially in regard to premenstrual pain and water retention. S.Thys-Jacobs,
- Another object of the present invention is to provide a composition for the treatment of PMS symptoms that achieves enhanced compliance from the patient and therefore better results because each of the active ingredients required to treat the various symptoms are provided within a single formulation.
- the present invention provides a method for treating premenstrual syndrome comprising administering an effective amount of calcium, magnesium, an analgesic and a diuretic so that the symptoms of premenstrual syndrome are reduced.
- the present invention is also directed to a composition for the relief of pain and discomfort associated with premenstrual syndrome comprising and effective amount of calcium, magnesium, an analgesic and a diuretic.
- composition according to the present invention is a formulation including at least four separate active ingredients: (1) magnesium; (2) calcium; (3) an analgesic; and (4) a diuretic.
- Aspirin acetylsalicylic acid
- acetaminophen acetaminophen
- ibuprofen are each effective analgesics within the scope of the present invention.
- the analgesic functions to relieve the symptoms of abdominal cramps, back pain and pain from swollen and tender breasts as well a ⁇ headache pain.
- the analgesic acetaminophen is administered in a dose of about 500 mg. four times a day for a total of about 2000 mg/day.
- the diuretic is provided to relieve symptoms related to water retention such a ⁇ excessive water weight, bloating, swelling, painful breasts, cramps and tension.
- the preferred diuretic within the scope of the present invention is pamabrom, a theophylline derivative.
- ammonium chloride, an acid-forming salt may be used.
- caffeine is not a preferred diuretic since it tends to extend the symptoms of PMS rather than provide relief.
- the diuretic is administered in a dose of about 25 mg four times a day for a total of about 100 mg/day.
- Elemental magnesium (Mg 2+ ) is provided for relief of "negative affect" i.e. premenstrual mood fluctuations.
- Mg cation supplementation must be sufficient to increase the cation content in both the lymphocytes and polymorphonuclear cells. This generally means a dosage higher than the recommended dietary allowances set by the National Academy of Sciences but low enough to avoid the risk of overload.
- Applicant has determined that the magnesium cation be administered in a dose of about 100 mg of magnesium four times a day for a total of about 400 mg/day.
- Preferred sources of magnesium ion for oral ingestion include magnesium glucoheptonate, magnesium pyrrolidone carboxylic acid, magnesium gluconate, magnesium pyroglutamate and magnesium sulfate.
- Elemental calcium provides relief for both the physical and behavioral symptoms of PMS. Behavioral symptoms are generally characterized a ⁇ "negative affect”. Within the meaning of the present invention these include depression, violent tendencies, crying, mood swings, irritability and nervousness. Physical symptoms treated by the calcium therapy according to the present invention include headache, back pain, water retention, abdominal bloating and cramps, breast tenderness and fatigue. Applicant has determined that the calcium be administered in a dose of about 300 mg four times a day for a total of about 1200 mg/day.
- the source of calcium for the formulation according to the present invention is in the form of calcium carbonate, calcium chloride, calcium glucoheptonate, calcium gluconate, calcium gluconogalactogluconate, calcium gluceptate, calcium lactate, calcium glubionate, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate and calcium phosphate tribasic.
- Both the magnesium and calcium within the scope of the present invention must be in a form to allow the ions to be readily adsorbed by the body.
- the above described calcium and magnesium compounds allow such absorption into the body.
- Antacid agents are to be avoided since magnesium or calcium cations are less readily adsorbed from such compounds.
- Example 1 The specific formulation set forth above produces optimal therapeutic results within the permissible deviation indicated. However, certain individual ingredients may vary in amount and still produce satisfactory results. The following specific examples are representative of the composition according to the present invention: Example 1
- composition according to the present invention is effective in treating all the major symptoms of PMS by provide a broad therapeutic spectrum.
- Each of the active ingredient ⁇ will address certain of the PMS symptoms.
- the overlapping nature of the active ingredient ⁇ within the method and composition of the present invention enhances the effectiveness of treatment while at the ⁇ ame time compensating for deficiencies of a particular ingredient.
- the magnesium will provide the greatest relief for water retention and negative affect. By itself, it has virtually no effect on the remaining symptoms.
- calcium provides a broad-based treatment for every one of the symptoms; "negative affect” and water retention are only somewhat improved.
- the analgesic component fills the remaining gaps in treatment, especially in regard to pain, headache and soreness while the diuretic targets water retention and its related symptoms.
- a broad-based , therapeutic spectrum is achieved having improvements over the prior art methods and formulations.
- Applicant believes that the present combination of active ingredients and method steps, especially those designed to address the same symptoms, produce a synergistic improvement in therapy over the individual ingredients alone. Since the applicant has selected active ingredients designed to address each of the various symptoms through different mechanisms of action, their cumulative effect produces improved treatment.
- the formulation of the present invention may be incorporated within any suitable carrier known in the art, for example sucrose or dextrose. It may be in tablet or capsule form, in chewable or effervescent tablet or in liquid form. Further, the formulation may be prepared as a sustained release capsule or tablet with the concentration of the active ingredients being that for the total daily dosage. While this invention has been described as having a preferred designs, it is understood that it is capable of further modifi ⁇ ations, uses and/or adaptations of the invention following in general the principle of the invention and including such departures from the present disclosure as come within the known or customary practice in the art to which the invention pertains and as may be applied to the central features hereinbefore set forth, and fall within the scope of the invention and of the limits of the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Une composition pour le traitement du syndrome prémenstruel comprend une quantité active de calcium, de magnésium, d'un analgésique et d'un diurétique, suffisante pour atténuer les symptômes du syndrome prémenstruel.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA1996/000229 WO1997038701A1 (fr) | 1996-04-12 | 1996-04-12 | Composition et procede pour le traitement du syndrome premenstruel |
| AU52655/96A AU5265596A (en) | 1996-04-12 | 1996-04-12 | Composition and method for the treatment of premenstrual syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA1996/000229 WO1997038701A1 (fr) | 1996-04-12 | 1996-04-12 | Composition et procede pour le traitement du syndrome premenstruel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997038701A1 true WO1997038701A1 (fr) | 1997-10-23 |
Family
ID=4173147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1996/000229 WO1997038701A1 (fr) | 1996-04-12 | 1996-04-12 | Composition et procede pour le traitement du syndrome premenstruel |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5265596A (fr) |
| WO (1) | WO1997038701A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841551B2 (en) * | 2000-01-18 | 2005-01-11 | Hoffmann-La Roche Inc. | Brain, spinal, and nerve injury treatment |
| EP3127546A1 (fr) * | 2015-08-06 | 2017-02-08 | Kenneth Davin Fine | Réduction d'absorption d'oxalate chez des individus |
| WO2018057737A1 (fr) * | 2016-09-22 | 2018-03-29 | Cash Alan B | Méthode pour soulager les symptômes du spm |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081823A1 (fr) * | 1981-12-10 | 1983-06-22 | WHITBY RESEARCH, Inc. | Composition pour diminuer les douleurs menstruelles |
| EP0246177A2 (fr) * | 1986-05-14 | 1987-11-19 | George H. Clark | Boisson et procédé de production d'une boisson, pour compléter la ration de calcium chez l'homme |
| US4888343A (en) * | 1986-09-15 | 1989-12-19 | Bristol-Myers Company | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process |
| US4946679A (en) * | 1988-07-25 | 1990-08-07 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome |
| CA2150417A1 (fr) * | 1994-10-14 | 1996-04-15 | Simon W. Rabkin | Composition pour le traitement du syndrome premenstruel et mode d'emploi |
-
1996
- 1996-04-12 AU AU52655/96A patent/AU5265596A/en not_active Abandoned
- 1996-04-12 WO PCT/CA1996/000229 patent/WO1997038701A1/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081823A1 (fr) * | 1981-12-10 | 1983-06-22 | WHITBY RESEARCH, Inc. | Composition pour diminuer les douleurs menstruelles |
| EP0246177A2 (fr) * | 1986-05-14 | 1987-11-19 | George H. Clark | Boisson et procédé de production d'une boisson, pour compléter la ration de calcium chez l'homme |
| US4888343A (en) * | 1986-09-15 | 1989-12-19 | Bristol-Myers Company | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process |
| US4946679A (en) * | 1988-07-25 | 1990-08-07 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome |
| CA2150417A1 (fr) * | 1994-10-14 | 1996-04-15 | Simon W. Rabkin | Composition pour le traitement du syndrome premenstruel et mode d'emploi |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841551B2 (en) * | 2000-01-18 | 2005-01-11 | Hoffmann-La Roche Inc. | Brain, spinal, and nerve injury treatment |
| US9186404B2 (en) | 2000-01-18 | 2015-11-17 | Eustralis Pharmaceuticals Limited | Brain, spinal and nerve injury treatment |
| US10201568B2 (en) | 2000-01-18 | 2019-02-12 | Eustralis Pharmaceuticals Limited | Brain, spinal, and nerve injury treatment |
| EP3127546A1 (fr) * | 2015-08-06 | 2017-02-08 | Kenneth Davin Fine | Réduction d'absorption d'oxalate chez des individus |
| WO2018057737A1 (fr) * | 2016-09-22 | 2018-03-29 | Cash Alan B | Méthode pour soulager les symptômes du spm |
| JP2019529559A (ja) * | 2016-09-22 | 2019-10-17 | アラン ビー． キャッシュ， | Ｐｍｓの症状を軽減する方法 |
| US11071722B2 (en) | 2016-09-22 | 2021-07-27 | Alan B. Cash | Method to alleviate the symptoms of PMS |
| JP7291079B2 (ja) | 2016-09-22 | 2023-06-14 | アラン ビー． キャッシュ， | Ｐｍｓの症状を軽減する方法 |
| AU2017330348B2 (en) * | 2016-09-22 | 2023-09-07 | Alan B. Cash | Method to alleviate the symptoms of PMS |
| US11865092B2 (en) | 2016-09-22 | 2024-01-09 | Alan B. Cash | Method to alleviate the symptoms of PMS |
| US12324794B2 (en) | 2016-09-22 | 2025-06-10 | Alan B. Cash | Method to alleviate the symptoms of PMS |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5265596A (en) | 1997-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5612061A (en) | Composition and method for the treatment of premenstrual syndrome | |
| US6500450B1 (en) | Composition for treating migraine headaches | |
| Saper et al. | Ergotamine tartrate dependency: features and possible mechanisms | |
| Sharma et al. | Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium | |
| DE69529213T2 (de) | Verwendung von magnesium enthaltenden verbindungen zur behandlung oder prophylaxe von krebs- und autoimmunkrankheiten | |
| US8129430B2 (en) | Method of reducing phosphate nephropathy in a mammal | |
| US4387093A (en) | Arthritis treatment | |
| US20030125303A1 (en) | Transdermal formulation for repair and maintenance of connective tissue | |
| WO1997038701A1 (fr) | Composition et procede pour le traitement du syndrome premenstruel | |
| CN1371291A (zh) | 用于缓解肿瘤和抑制癌症的方法和制剂 | |
| DE3500670A1 (de) | Diphosphonate enthaltende arzneimittel | |
| EP1784177B1 (fr) | Formulation pour l-tryptophane comprenant du carbidopa-benserazide | |
| Diamond et al. | Fenoprofen in the Prophylaxis of Migraine: A Double—Blind, Placebo Controlled Study | |
| US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
| EP3693020A1 (fr) | Formulations topiques enrichies en potassium pour le soulagement de la douleur et l'aide du sommeil | |
| DE3936319C2 (fr) | ||
| DE102022103658A1 (de) | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer | |
| WO2003022292A1 (fr) | Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| JPH061721A (ja) | 疼痛処置剤、及び疼痛軽減作用増強剤 | |
| EP0018550A2 (fr) | Compositions pour le traitement de maladies musculaires | |
| Fazio et al. | Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor | |
| JP2024061731A (ja) | 片頭痛の予防及び治療に使用するための栄養補助食品 | |
| Janicak et al. | Verapamil for acute mania: preliminary results from a double-blind, placebo-controlled study | |
| US4385064A (en) | Method for treating sickle cell anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP MX |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97536595 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |